Systemic Efficacy of Sirolimus via the ERBB Signaling Pathway in Breast Cancer

Rapamycin, also known as sirolimus, inhibits the mTOR pathway in complex diseases such cancer, and its downstream targets are ribosomal S6 kinases (RPS6K). Sirolimus is involved regulating cell growth survival through roles mediation of epidermal factor signaling. However, systemic efficacy sirolimus regulation unclear. The purpose this study to determine drug using computational methods drug-induced datasets. We suggest a method gene expression datasets induced by an inverse algorithm that simultaneously identifies parameters referring gene–gene interactions. downloaded two sirolimus-induced microarray used obtain most enriched pathway, then adopted discover interactions pathway. In results, RPS6KB1 was target associated with genes common from were hub gene, RPS6KB1, 10 related (AKT3, CBLC, MAP2K7, NRG1/2, PAK3, PIK3CD/G, PRKCG, SHC3) (ERBB) signaling